RT Journal Article
SR Electronic
T1 Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20169300
DO 10.1101/2020.08.06.20169300
A1 Laura Pasetto
A1 Stefano Callegaro
A1 Deborah Ferrara
A1 Laura Brunelli
A1 Giovanna Sestito
A1 Roberta Pastorelli
A1 Elisa Bianchi
A1 Alessandro Corbelli
A1 Fabio Fiordaliso
A1 Marina Cretich
A1 Marcella Chiari
A1 Cristina Potrich
A1 Cristina Moglia
A1 Massimo Corbo
A1 Gianni Sorarù
A1 Christian Lunetta
A1 Andrea Calvo
A1 Adriano Chiò
A1 Gabriele Mora
A1 Maria Pennuto
A1 Alessandro Quattrone
A1 Francesco Rinaldi
A1 Vito D’Agostino
A1 Manuela Basso
A1 Valentina Bonetto
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.06.20169300.abstract
AB Amyotrophic lateral sclerosis is a multifactorial and multisystem motor neuron disease with currently no effective treatment. There is an urgent need to identify biomarkers that can tackle the disease’s complexity and help in early diagnosis, prognosis, and therapy development. Extracellular vesicles (EVs) are nanostructures that are released by any cell type into body fluids. Their variable biophysical and biochemical characteristics reflect the parent cell’s physiological and pathological state and make them an attractive source of multidimensional data for patient classification and stratification. To test whether EVs could be exploited as diagnostic and prognostic biomarkers in ALS, we analyzed plasma-derived EVs of ALS patients and relative healthy and diseased controls. Using the nickel-based isolation, a recently developed EV purification method, we unmasked peculiar features in plasma EVs of ALS patients with a potential straightforward application in a clinical setting. We report that the number of particles is increased in the plasma of ALS patients and two mouse models of ALS while the average diameter is decreased. Proteins like HSP90 and phosphorylated TDP-43 are differentially represented in ALS patients and mice compared to the controls. In terms of disease progression, the levels of phosphorylated TDP-43 and cyclophilin A, along with the EV size distribution, discriminated fast and slow disease progressors suggesting a new means for patient stratification. Finally, we conceived an innovative mathematical model based on machine learning techniques that integrating EV size distribution data with biochemical EV parameters resulted in very high prediction rates for disease diagnosis and prognosis.Competing Interest StatementVDA and AQ declare competing interests for the patent application of the NBI procedure (WO2019122003).Funding StatementThis study has been supported by grants listed in the relative paragraph of the textAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments have been conducted upon approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability All the data generated for this manuscript are available upon requests to the corresponding authors. Proteomics The whole mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org/cgi/GetDataset) via the PRIDE partner repository with the data set identifier PXD020629